NCT06807970Active, not recruitingEarly phase 1
Optimization of Obesity for Total Knee Replacement With Glucagon-like Peptide-1 Receptor Agonist
Novel Perioperative Optimization of Obese Osteoarthritic Patients Pending Total Knee Replacement With Glucagon-like Peptide-1 Receptor Agonist (NPO-OOPS-TKR)
Source: ClinicalTrials.gov · Last updated 19 Aug 2026
Brief summary (registry, in English)
Studies have shown that obese patients undergoing total knee replacement (TKR) surgery face a higher risk of perioperative issues such as increased use of pain medication, surgical site infections, and the need for revision surgeries compared to non-obese patients. Obesity is also linked to more significant preoperative pain and lingering symptoms post-surgery. Consequently, there's a growing interest in weight loss interventions prior to TKR to enhance perioperative care and outcomes. Recent retrospective studies have indicated that such interventions can improve physical function post-TKR. Research focusing on weight loss interventions before joint replacement surgery is limited. There is currently a gap in research regarding RCTs on weight loss interventions using anti-obesity drugs before TKR, particularly in Asian populations. One promising avenue under exploration involves the use of glucagon-like peptide 1 receptor agonists (GLP-1RAs) as anti-obesity medication before total knee replacement (TKR) surgery. However, there are currently no randomized controlled trials (RCTs) examining the effects of GLP-1RAs on knee arthroplasty outcomes. Large database studies have indicated that GLP-1RAs may decrease the likelihood of certain post-surgery complications but increase the risk of others. In summary, addressing obesity through weight loss interventions, particularly with GLP-1RAs, holds promise for improving outcomes in TKR patients. However, further research, including randomized controlled trials, is necessary to fully understand the effects of GLP-1RAs on perioperative outcomes and patient health.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 54 (estimated)
- First submitted
- 15 Jan 2025
- Start date
- 1 Sept 2025
- Primary completion date
- 1 Jul 2027
- Lead sponsor
- The University of Hong Kong
- Diseases
- Obesity
- NCT number
- NCT06807970
What you commit to
- Study type: Interventional · Early phase 1
- Planned participants: 54
- From 1 Sept 2025 to the primary completion date, 1 Jul 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Revision surgery or surgery for neoplastic disease
- A medical condition which in the opinion of the investigators makes the patient unsuitable for participation in the trial
- Contraindication to GLP-1RA, like history of pancreatitis, severe gastrointestinal diseases such as gastroparesis, thyroid cancer, and inflammatory bowel disease
Other
- Lack of acceptance of the randomisation process.
Who the study is looking for
- Age between 40 and 80 years old
- BMI ≥27 kg/m2
- On the surgical waiting list for primary TKR
- Willing and able to cooperate in a weight management programme.
- Meeting indication for semaglutide
Age in the registry: 40 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Queen Mary Hospital Coordinator of this site? Confirm its status | Hong Kong | Hong Kong SAR China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.